Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine

Clinical Cancer Research

Volumn 12, Issue 2, 2006, Pages 432-441

  Ye, Bin ^a   Skates, Steven ^b   Mok, Samuel C ^a   Horick, Nora K ^b   Rosenberg, Helene F ^c   Vitonis, Allison ^a   Edwards, Dale ^a   Sluss, Patrick ^b   Han, Won K ^a   Berkowitz, Ross S ^a   Cramer, Daniel W ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EOSINOPHIL PROTEIN X; OSTEOPONTIN; PROTEIN;

ADULT; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GYNECOLOGIC CANCER; HUMAN; IMMUNOPRECIPITATION; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; OVARY CANCER; PELVIS TUMOR; PEPTIDE ANALYSIS; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; PROTEIN PURIFICATION; PROTEIN URINE LEVEL; TWO DIMENSIONAL GEL ELECTROPHORESIS; URINALYSIS; WESTERN BLOTTING;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; AMINO ACID SEQUENCE; CARCINOMA, ENDOMETRIOID; CASE-CONTROL STUDIES; CYSTADENOCARCINOMA, SEROUS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EOSINOPHIL-DERIVED NEUROTOXIN; FEMALE; GLYCOSYLATION; HUMANS; MOLECULAR SEQUENCE DATA; NEOPLASM INVASIVENESS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OSTEOPONTIN; OVARIAN NEOPLASMS; PROGNOSIS; PROTEOME; SIALOGLYCOPROTEINS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 31544440478     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0461     Document Type: Article

References (48)

1. Jacobs IJ, Skates SJ, MacDonald N, et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 1999;353:1207-10.
2. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572-7.
3. Kumar S, Tsai CJ, Nussinov R. Temperature range of thermodynamic stability for the native state of reversible two-state proteins. Biochemistry 2003;42:4864-73.
4. Marshall T, Williams K. Two-dimensional electrophoresis of human urinary proteins following concentration by dye precipitation. Electrophoresis 1996;17:1265-72.
5. Pieper R, Gatlin CL, McGrath AM, et al. Characterization of the human urinary proteome: a method for high-resolution display of urinary proteins on two-dimensional electrophoresis gels with a yield of nearly 1400 distinct protein spots. Proteomics 2004;4:1159-74.
6. Cramer DW, Greenberg ER, Titus-Ernstoff L, et al. A case-control study of galactose consumption and metabolism in relation to ovarian cancer. Cancer Epidemiol Biomarkers Prev 2000;9:95-101.
7. Ye B, Cramer DW, Skates SJ, et al. Haptoglobin-α subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin Cancer Res 2003;9:2904-11.
8. Mann M, Hendrickson RC, Pandey A. Analysis of proteins and proteomes by mass spectrometry. Annu Rev Biochem 2001;70:437-73.
9. Shevchenko A, Wilm M, Vorm O, Mann M. Mass spectrometric sequencing of proteins silver-stained poly-acrylamide gels. Anal Chem 1996;68:850-8.
10. Rosenberg HF, Dyer KD, Li F. Characterization of eosinophils generated in vitro from CD34+ peripheral blood progenitor cells. Exp Hematol 1996;24:888-93.
11. Porat YB, Zan-Bar I, Ravid A. Quantitative dot-blot assay for low titer anti-lipopolysaccharide antibodies in human plasma. J Immunol Methods 1995;180:213-8.
12. Nezlin RA. Quantitative approach to the determination of antigen in immune complexes. J Immunol Methods 2000;237:1-17.
13. Hitoi A, Yamashita K, Niwata Y, Irie M, Kochibe N, Kobata A. The carbohydrate moieties of human urinary ribonuclease UL. J Biochem (Tokyo) 1987;101:29-41.
14. Beintema JJ, Blank A, Schieven GL, Dekker CA, Sorrentino S, Libonati M. Differences in glycosylation pattern of human secretory ribonucleases. Biochem J 1988;255:501-5.
15. Kim JH, Skates SJ, Uede T, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002;287:1671-9.
16. Diamandis EP, van der Merwe DE. Plasma protein profiling by mass spectrometry for cancer diagnosis: opportunities and limitations. Clin Cancer Res 2005;11:963-5.
17. Alper J. Glycobiology. Turning sweet on cancer. Science 2003;301:159-60.
18. Hakomori S. Glycosylation defining cancer malignancy: new wine in an old bottle. Proc Natl Acad Sci U S A 2002;99:10231-3.
19. Roy R, Wewer UM, Zurakowski D, Pories SE, Moses MA. ADAM 12 cleaves ECM proteins: correlation with cancer status and stage. J Biol Chem 2004;279:51323-30.
20. Brouwers FM, Petricoin EF III, Ksinantova L, et al. Low molecular weight proteomic information distinguishes metastatic from benign pheochromocytoma. Endocr Relat Cancer 2005;12:263-72.
21. Schwartz RS. The hypereosinophilic syndrome and the biology of cancer. N Engl J Med 2003;348:1199-200.
22. Samoszuk M. Eosinophils and human cancer. Histol Histopathol 1997;12:807-12.
23. Ali S, Kaur J, Patel KD. Intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and regulated on activation normal T cell expressed and secreted are expressed by human breast carcinoma cells and support eosinophil adhesion and activation. Am J Pathol 2000;157:313-21.
24. Kodama T, Takada K, Kameya T, Shimosato Y, Tsuchiya R, Okabe T. Large cell carcinoma of the lung associated with marked eosinophilia. A case report. Cancer 1984;54:2313-7.
25. Fernandez-Acenero MJ, Galindo-Gallego M, Sanz J, Aljama A. Prognostic influence of tumor-associated eosinophilic infiltrate in colorectal carcinoma. Cancer 2000;88:1544-8.
26. Samoszuk M, Lin F, Rim P, Strathearn G. New marker for blood vessels in human ovarian and endometrial cancers. Clin Cancer Res 1996;2:1867-71.
27. Blumenthal RD, Samoszuk M, Taylor AP, Brown G, Alisauskas R, Goldenberg DM. Degranulating eosinophils in human endometriosis. Am J Pathol 2000;156:1581-8.
28. Schleich HG, Wiest W, Schmidt R, Hofmann I, Altenburg HP, Melchert F. Ovarian carcinoma: increase in clinical validity by simultaneous determination of SRA and CA 125. J Cancer Res Clin Oncol 1987;113:603-7.
29. Rosenberg HF. The eosinophil ribonucleases. Cell Mol Life Sci 1998;54:795-803.
30. Sakakibara R, Hashida K, Kitahara T, Ishiguro M. Characterization of a unique nonsecretory ribonuclease from urine of pregnant women. J Biochem (Tokyo) 1992;111:325-30.
31. Sakakibara R, Hashida K, Tominaga N, et al. A putative mouse oocyte maturation inhibitory protein from urine of pregnant women: N-terminal sequence homology with human nonsecretory ribonuclease. Chem Pharm Bull (Tokyo) 1991;39:146-9.
32. Kauffman HF, Hovenga H, de Bruijn HW, Beintema JJ. Eosinophil derived neurotoxin (EDN) levels in commercial human urinary preparations of glycoprotein hormones. Eur J Obstet Gynecol Reprod Biol 1999;82:111-3.
33. Konishi I, Kuroda H, Mandai M. Review: gonadotropins and development of ovarian cancer. Oncology 1999;57 Suppl 2:45-8.
34. Yamashita K, Hitoi A, Irie M, Kobata A. Fractionation by lectin affinity chromatography indicates that the glycosylation of most ribonucleases in human viscera and body fluids is organ specific. Arch Biochem Biophys 1986;250:263-6.
35. Weber GF, Cantor H. The immunology of Eta-1/osteopontin. Cytokine Growth Factor Rev 1996;7:241-8.
36. Denhardt DT, Chambers AF. Overcoming obstacles to metastasis-defenses against host defenses: osteopontin (OPN) as a shield against attack by cytotoxic host cells. J Cell Biochem 1994;56:48-51.
37. Yokosaki Y, Matsuura N, Sasaki T et al. The integrin α(9)β(1) binds to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin. J Biol Chem 1999;274:36328-34.
38. Agnihotri R, Crawford HC, Haro H, Matrisian LM, Havrda MC, Liaw L. Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin). J Biol Chem 2001;276:28261-7.
39. Fedarko NS, Jain A, Karadag A, Fisher LW. Three small integrin binding ligand N-linked glycoproteins (SIBLINGS) bind and activate specific matrix metalloproteinases. FASEB J 2004;18:734-6.
40. Karadag A, Ogbureke KU, Fedarko NS, Fisher LW. Bone sialoprotein, matrix metalloproteinase 2, and α(ν)β3 integrin in osteotropic cancer cell invasion. J Natl Cancer Inst 2004;96:956-65.
41. Venge P. Monitoring the allergic inflammation. Allergy 2004;59:26-32.
42. Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 2001;107:1055-61.
43. O'Regan A, Berman JS. Osteopontin: a key cytokine in cell-mediated and granulomatous inflammation. Int J Exp Pathol 2000;81:373-90.
44. O'Regan A, Fleming C. Osteopontin as a biomarker for ovarian cancer. JAMA 2002;287:3208-9; author reply 3209-10.
45. Seidman JD. Osteopontin as a biomarker for ovarian cancer. JAMA 2002;287:3209; author reply 3209-10.
46. Terry KL, Sluss PM, Skates SJ, et al. Blood and urine markers for ovarian cancer: a comprehensive review. Dis Markers 2004;20:53-70.
47. Koomen JM, Shih LN, Coombes KR, et al. Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. Clin Cancer Res 2005;11:1110-8.
48. Zhang Z, Bast RC, Jr., Yu Y, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004;64:5882-90.